The Multifaceted Function of Granzymes in Sepsis: Some Facts and a Lot to Discover by Garzon-Tituana, M et al.
REVIEW
published: 17 June 2020
doi: 10.3389/fimmu.2020.01054
Frontiers in Immunology | www.frontiersin.org 1 June 2020 | Volume 11 | Article 1054
Edited by:
Francesca Velotti,
University of Tuscia, Italy
Reviewed by:
David J. Granville,
University of British Columbia, Canada
Vanessa Pinho,





†These authors have contributed
equally to this work
Specialty section:
This article was submitted to
Cytokines and Soluble Mediators in
Immunity,
a section of the journal
Frontiers in Immunology
Received: 11 March 2020
Accepted: 30 April 2020
Published: 17 June 2020
Citation:
Garzón-Tituaña M, Arias MA,
Sierra-Monzón JL, Morte-Romea E,
Santiago L, Ramirez-Labrada A,
Martinez-Lostao L, Paño-Pardo JR,
Galvez EM and Pardo J (2020) The
Multifaceted Function of Granzymes in
Sepsis: Some Facts and a Lot to
Discover. Front. Immunol. 11:1054.
doi: 10.3389/fimmu.2020.01054
The Multifaceted Function of
Granzymes in Sepsis: Some Facts
and a Lot to Discover
Marcela Garzón-Tituaña 1†, Maykel A. Arias 2†, José L. Sierra-Monzón 1,3,
Elena Morte-Romea 1,3, Llipsy Santiago 1, Ariel Ramirez-Labrada 4,
Luis Martinez-Lostao 1,3,5, José R. Paño-Pardo 1,3, Eva M. Galvez 2 and Julián Pardo 1,5,6,7,8*
1 Fundación Instituto de Investigación Sanitaria Aragón (IIS Aragón), Biomedical Research Centre of Aragón (CIBA),
Zaragoza, Spain, 2 Instituto de Carboquímica ICB-CSIC, Zaragoza, Spain, 3Hospital Clínico Universitario Lozano Blesa,
Zaragoza, Spain, 4Nanotoxicology and Immunotoxicology Unit (UNATI), Fundación Instituto de Investigación Sanitaria
Aragón (IIS Aragón), Zaragoza, Spain, 5Nanoscience Institute of Aragon (INA), University of Zaragoza, Zaragoza, Spain,
6 Aragon I + D Foundation (ARAID), Zaragoza, Spain, 7Department of Biochemistry and Molecular and Cell Biology and
Department of Microbiology, Preventive Medicine and Public Health, University of Zaragoza, Zaragoza, Spain, 8Centro de
Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Madrid, Spain
Sepsis is a serious global health problem. In addition to a high incidence, this syndrome
has a high mortality and is responsible for huge health expenditure. The pathophysiology
of sepsis is very complex and it is not well-understood yet. However, it is widely accepted
that the initial phase of sepsis is characterized by a hyperinflammatory response while the
late phase is characterized by immunosuppression and immune anergy, increasing the
risk of secondary infections. Granzymes (Gzms) are a family of serine proteases classified
according to their cleavage specificity. Traditionally, it was assumed that all Gzms acted
as cytotoxic proteases. However, recent evidence suggests that GzmB is the one with
the greatest cytotoxic capacity, while the cytotoxicity of others such as GzmA and GzmK
is not clear. Recent studies have found that GzmA, GzmB, GzmK, and GzmM act
as pro-inflammatory mediators. Specially, solid evidences show that GzmA and GzmK
function as extracellular proteases that regulate the inflammatory response irrespectively
of its ability to induce cell death. Indeed, studies in animal models indicate that GzmA is
involved in the cytokine release syndrome characteristic of sepsis. Moreover, the GZM
family also could regulate other biological processes involved in sepsis pathophysiology
like the coagulation cascade, platelet function, endothelial barrier permeability, and, in
addition, could be involved in the immunosuppressive stage of sepsis. In this review, we
provide a comprehensive overview on the contribution of these novel functions of Gzms
to sepsis and the new therapeutic opportunities emerging from targeting these proteases
for the treatment of this serious health problem.
Keywords: sepsis, inflammatory cytokine, granzymes, coagulopathy, endothelial (dys)function,
immunosuppression
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INTRODUCTION
The immune system is the most important line of defense against
pathogens. The immune response to infection is initiated after the
recognition of pathogen derived molecules known as Pathogen
Associated Molecular Patterns (PAMPs) by specific receptors
known as PAMP receptors. This process triggers the production
of inflammatory, angiogenic, and chemotactic factors involved
in the activation of innate and adaptive immune mechanisms
leading to pathogen clearance, tissue repair, and resolution of
the inflammatory response. However, if not properly regulated,
inflammation may act as a double-edged sword that can trigger
serious complications like sepsis. This syndrome is an important
health problem, defined as “a life-threatening organ dysfunction
caused by a dysregulated host response to infection” (1).
Recent epidemiological studies estimate an annual incidence of
48.9 million sepsis cases with 11 million sepsis-related deaths
representing 20% of all global deaths (2).
The pathophysiology of sepsis is very complex and it
is not well-understood yet. Simultaneous and interrelated
inflammatory and anti-inflammatory responses are developed
(3, 4), although it is widely accepted that the initial phase of
sepsis is characterized by a hyperinflammatory response while
the late phase is characterized by immunosuppression and
immune anergy that increases the risk of other opportunistic
infections, specially bacterial and fungal. These opposite
reactions hamper the development of effective treatments
to reduce the inflammatory damage, and, at the same
time, do not increase the risk or even help to prevent
secondary infections. Indeed, most experimental trials to
reduce the inflammatory response with general or specific
anti-inflammatory molecules targeting PAMPs like endotoxin,
PAMPRs like TLR4, complement, cytokines, or coagulation
factors have not positively impacted on patient survival (5).
The reasons for the low efficacy of anti-inflammatory therapy
are not clear since reduction of tissue damage and coagulation
syndrome together with an effective antimicrobial therapy should
be beneficial to improve disease outcome. One reason could
be that anti-inflammatory therapy might reduce host pathogen
clearance due to inhibition of inflammatory pathways important
for the protective immune response against the infection
responsible of sepsis (5). In addition, it is not clear yet whether
the anti-inflammatory therapies tested up to now are able to
prevent immunosuppression and anergy during sepsis. Thus,
although molecules involved in exacerbated inflammation and
coagulation like inflammatory cytokines (i.e., IL6, IL1, TNFα)
have shown a good prognostic value for sepsis progression and
severity, targets to regulate inflammation without compromising
host immune response against the sepsis-inducing pathogen or
against secondary infections have not been found yet. Recently,
some members of a family of serine-proteases named granzymes
(Gzms), that are expressed by immune and non-immune cells
(6), have been found in extracellular human fluids of different
inflammatory disorders like sepsis. In addition, they have been
found to regulate the inflammatory response in vitro and in
vivo during different inflammatory disorders related to infections
like sepsis.
The granule exocytosis pathway is a specialized form of
intracellular protein delivery by which lymphocytes release
perforin and Gzms. Perforin exerts its action allowing the
passage of granzymes into the cytosol of target cells to carry
out their effector functions, including cytotoxic and non-
cytotoxic functions (7). On the other hand, Gzms can be
released into the extracellular milieu where they will exert some
extracellular functions including regulation of inflammation,
pathogen inactivation, or extracellular matrix remodeling (6, 8).
Gzms are a family of serine proteases classified according to their
cleavage specificity. Five Gzms in humans (A, B, H, K, and M)
and 10 in mice (A, B, C, D, E, F, G, K, M, and N) have been
described. GzmA and GzmB are the most abundant and best
characterized (6). Traditionally, it was assumed that all Gzms
acted as cytotoxic proteases. However, recent evidence suggests
that intracellulary-delivered GzmB is the one with the greatest
cytotoxic capacity, while the cytotoxicity of others such as GzmA
and GzmK is in controversy (7, 9–13). A recent study has shown
that GzmA might mediate pyroptotic cell death in human and
mouse tumor cells (14), although the relevance of this finding
needs to be confirmed in different experimental models, since
it has been previously reported that the cytotoxic potential of
intracellulary-delivered GzmA might differ between mouse and
human (15). Regarding human GzmH, a few studies have shown
that it can induce cell death and inactivate viral proteins (7).
However, at present there is not any study correlating GzmHwith
the regulation of the inflammatory response or sepsis, and, thus,
GzmH will not be further discussed in this review.
Recent studies have found that GzmA, GzmB, GzmK, and
GzmM act as pro-inflammatory mediators and could be involved
in the pathophysiology of sepsis (7, 10–12) (Table 1 and
Figure 1). Thus, a detailed study of Gzms in different sepsis
models as well as in patients undergoing different types of
sepsis might provide new prognostic factors and therapeutic
targets to overcome some of the limitations observed for
other inflammation-related targets. This hypothesis is supported
by different previous experimental findings indicating that
deficiency in any single Gzm does not significantly reduce
pathogen clearance, and, thus, their inhibition during sepsis
would reduce inflammation without compromising host anti-
pathogen immunity (6).
In this review, we will present the available evidence in
animal models and humans that suggests that Gzms might have
a relevant role in sepsis pathophysiology. In addition, we will
discuss the potential advantages of using Gzms as therapeutic
targets to reduce organ damage without compromising pathogen
clearance and to prevent immunosuppression-associated
secondary infections. Since novel functions of Gzms, non-related
with its ability to induce cell death, have emerged in the last years,
we will focus on the potential impact of these non-cytotoxic
functions in the pathophysiology of sepsis. Some of them are
originated in in vitro studies in non-sepsis models. However,
since several of these non-cytotoxic functions (explained in more
detail in the following sections) form part of the pathophysiology
of sepsis, we think that it will be useful to discuss its potential
impact on sepsis, indicating when appropriate the needed to
specifically confirm their relevance in sepsis.
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GRANZYMES ARE ELEVATED IN PATIENTS
SUFFERING FROM SEPSIS
Some studies have analyzed the presence of soluble Gzms in fluids
from patients suffering from sepsis. These data show an increase
in cellular and serum levels of some Gzms like GzmA, GzmB,
and GzmK. Increased levels of GzmA and GzmB have been
found in patients with severe gram negative bacterial infections as
well as in healthy volunteers with an experimental endotoxemia
with lipopolysaccharide (LPS) (31). GzmM and GzmK were also
found in serum from volunteers with experimental endotoxemia
(32) and GzmM was also elevated in serum from meningococcal
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m, mouse; h, human; PAR, protease activated receptor; TLR, Toll like receptor. bExtracellular GzmM cleaves vWF, releasing it from endothelial cell membrane and regulating its
procoagulatory activity.
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FIGURE 1 | The potential contribution of the non-cytotoxic functions of granzymes to the pathophysiology of sepsis. Gzms can be released to the extracelular millieu
by different cell types including NK cells, T cells, mast cells, platelets, or other cells stimulated by molecules presented in pathogens (fungal, bacterial, or viral PAMPs)
or released by damaged cells (DAMPs) during sepsis. There different Gzms could contribute to different alterations found during sepsis like the inflammatory cytokine
storm, blood clotting, cardiovascular disorders (coagulation and endotelial permeability), or immunosuppresion as described in the text. Abbreviations: Breg,
regulatory B cell; MDSC, myeloid-derived suppressor cell; NK, natural killer; Tc, cytotoxic T cell; Th1, type 1 T helper cell; Treg, regulatory T cell; VWF, Von Willebrand
factor; proUK, prourokinase; Fn, fibrin.
sepsis (30). In contrast, GzmA levels were reduced in plasma
during sepsis in burned patients (33). This result suggests that the
level of GzmA in septic patients might depend on the underlying
cause of sepsis. Supporting this hypothesis, Wensink et al. also
showed that the release of GzmK and GzmM from human
peripheral blood lymphocytes depended on the bacteria used for
the stimulation (32). GzmK has also been found in the plasma of
patients with sepsis as well as in bronchioalveolar fluid of patients
with viral pneumonia (34, 35). However, the clinical significance
of all these observations remains unknown.
A key question to understand the potential significance
of soluble Gzms in sepsis is the regulation of its activity
at the extracellular milieu. Like other proteases intracellular
and extracellular Gzms might be tightly regulated to avoid
unregulated proteolysis and cell/tissue damage. The main natural
inhibitors that control Gzm activity are members of the Serpin
(Serineprotease inhibitor) family. Different serpins have been
found to inhibit extracellular Gzms like Inter-alpha-trypsin
inhibitors (IaIs) (GzmA and GzmK), antithrombin III (GzmA),
or bikunin (GzmK) (36). Thus, if extracellular Gzms are expected
to play any role during sepsis it should be expected that they are
not counteract by those inhibitors. Confirming this hypothesis
and supporting a role for extracellular Gzms in sepsis it has been
described that the levels of these inhibitors in plasma are reduced
during sepsis. Indeed its concentration inversely correlated with
mortality (37, 38).
Regarding the clinical utility of Gzms in sepsis prognosis, it
was found that increased levels of GzmA and GzmB in CD8+T
cells were associated with a worse prognosis in severe sepsis
patients (39). Pending of validating the clinical significance of
the presence of soluble Gzms in septic patients, studies in animal
models in vivo indicate a key role for some Gzms like GzmA and
GzmM in inflammation and sepsis. GzmA deficiency has been
shown to protect against LPS-induced endotoxicosis (17, 40) as
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well as against sepsis induced by different bacterial pathogens
including gram negative Brucella microti (41) or gram positive
Streptococcus pneumoniae (42). These results suggest that the
involvement of GzmA in sepsis is not related with Gram bacterial
characteristics. Similarly, GzmM deficiency protects against LPS-
induced endotoxicosis (40). In contrast, GzmB deficiency did
not affect LPS-induced endotoxicosis (17, 40) or bacterial-
induced sepsis (41). Importantly, increased survival in GzmA or
GzmM deficient mice correlated with a reduction of the cytokine
storm as measured by the levels of inflammatory cytokines
in serum, organ damage, and coagulation activity confirming
amelioration of the main sepsis pathological consequences.
The course of sepsis in GzmK deficient mice remains to
be elucidated.
The activity of Gzms during infectious diseases and sepsis
seems to differ between anatomical site as well as the type of
pathogen involved. For instance, a study showed that there was
low level of GzmA in peritoneal lavage fluid of healthy mice
while this level increased overtime during sepsis induced by E.
coli (43). On the other hand, in a pneumonia-induced sepsis
using a gram positive bacteria (Streptococcus pneumoniae) model
the opposite was found (42). Here a small remark between the
differences found in the pathophysiology of sepsis induced by
gram negative and gram positive bacteria should be included.
The onset and severity of sepsis may be defined by the molecular
pathway involved in the activation of the immune system and
the cytokines that can be induced in each case, both of which
depend on the PAMPs expressed by the pathogen. Traditionally,
the main responsible pathogens of sepsis have been considered
gram negative bacteria. Nevertheless, it has been reported that
gram positive bacteria are responsible for an ever-increasing
number of septic events and have become the most frequent
cause of sepsis, matching or even exceeding the sepsis caused
by gram negative bacteria (44). It is known that the main
receptors involved in the recognition of gram positive and
negative bacteria are TLRs 2 and 4, respectively. This may be
helpful for future studies and developments of sepsis treatments
(44) and might help to explain the differences found regarding
GzmA. For instance, a higher expression of IL-1β and IL-18 may
indicate that the infection is due to a gram + bacteria while IL-
6 and TNF would have a higher expression in gram negative
infections (44). Indeed, GzmA has been found to produce
very high levels of IL6 and TNF (Santiago et al. Cell Reports,
Under review).
The inflammatory effect of GzmA does not seem to
regulate bacterial control as GzmA deficient mice efficiently
control infections like Mycobacterium tuberculosis, Listeria
monocytogenes, Brucella microti, Klebsiella pneumoniae,
Streptococcus pneumoniae, or Escherichia coli (6). Based on
these experimental evidences it could be hypothesized that by
targeting GzmA, bacteria-associated sepsis could be ameliorated
without compromising the ability of the immune system to
control infection. Thus, these findings open the opportunity to
treat sepsis without causing immunosuppression and provide a
new opportunity to overcome some of the limitations of other
inflammatory targets unsuccessfully tested in clinical trials up
to now.
WHICH COULD BE THE MECHANISMS
BEHIND THE INFLAMMATORY ACTION OF
Gzms IN SEPSIS?
Several biological functions of Gzms that could contribute to the
different alterations found in sepsis have been described. Mainly
those related with the regulation of inflammatory responses,
the coagulation cascade, and changes in vascular permeability
(summarized in Figure 1). In this section we will describe the
mechanisms activated by Gzms that could potentially contribute
to the pathophysiology of sepsis with a special focus on the
hyperinflammatory stage.
Regulation of Inflammatory Cytokine
Networks and Cytokine Storm
The hyperinflammatory response in sepsis is characterized by
high levels of pro- and anti-inflammatory cytokines like IL-1β,
IL-1α, IL-18, IL-17, TNFα, IL-6, MIF, HMGB1, IL-10, IL-4, and
IL-13 (3, 45). This stage is also characterized by coagulation
disorders, interstitial edema, hypotension, reduced perfusion,
tissue hypoxia, mitochondrial dysfunction, and cell death (3, 4).
It has been shown that extracellular GzmA is able to induce
the production of different inflammatory cytokines such as IL-
1β, TNF-α IL-6, or IL-8 in both mouse and human cells like
monocytes, macrophages, fibroblasts, endothelial and epithelial
cells (17, 20) (Table 1) which might contribute to the cytokine
storm observed during sepsis. Indeed,most cytokines are reduced
in GzmA deficient mice suffering from sepsis as indicated above.
One of the first described substrates for GzmA is pro-interleukin
1β (pro IL-1 β), which after removal of the N-terminal part,
generates the active inflammatory form IL-1β (46). However,
direct cleavage of proIL1β and activation of IL1β has not
been subsequently confirmed by different authors. Alternatively
it has been reported that GzmA regulate the generation of
inflammatory cytokines in human monocytes by caspase-1 and
TLR4 dependent pathways (17, 18). Some other studies have
reported that mouse GzmA is able to activate PAR1, a member
of the Protease Activated Receptor (PAR) family, in mouse
neurons (21). Since PARs are involved in platelet activation
and thrombosis it could be suggested that PARs are involved
in GzmA-mediated inflammation and coagulation alterations.
However, as discussed below, the roles of PAR1 and 2 in sepsis
are not clear yet and thus, in vivo extrapolation of all these results
generated in vitro should be done with caution (47).
Alternatively, GzmA has been proposed to potentiate the
effects of LPS on human monocytes by a mechanism dependent
on TLR4 (19). Here authors showed that enzyme activity was
not required for this effect, albeit the underlying mechanism
was not clarified. This result contradicts previous findings
that showed that human inactive GzmA was not able to
induce the production of inflammatory cytokines in human
monocytes (17). In addition, it has been shown that the
inflammatory activity of mouse GzmA in vivo is significantly
affected when GzmA inactivated with an inhibitor is used (48).
The reasons for this discrepancy are not clear yet and will require
further investigation.
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GzmKdisplays a tryptase-like activity similar, but not identical
(49, 50) to GzmA, and it might also induce the production of
proinflammatory cytokines (Table 1). Nanomolar concentrations
of GzmK induce thematuration and secretion of IL-1β suggesting
that GzmK may augment GzmA-induced proinflammatory
processes by differentially cleaving the same or different specific
substrates (29). GzmK has also been found to activate PAR-1 in
endothelial and fibroblast cells and to induce the generation of
inflammatory cytokines (27, 28). However, as indicated above,
its role in sepsis remains to be elucidated. Finally, as it has been
previously discussed, GzmM is involved in endotoxicosis (40)
although it is not known if GzmM is able to directly modulate
inflammation on target cells (51).
The Coagulation Cascade
Systemic inflammation activates coagulation and inhibits
anticoagulant and fibrinolytic mechanisms which leads to a
dysregulated procoagulant state (52). The tissue factor (TF),
expressed in monocytes and microparticles from living or
apoptotic cells, is the responsible of the coagulation cascade
activating factor VII forming the FT/VIIa complex which
activates complexes IX and X. All of these play an important role
in platelet activation (53, 54). TF is the main initiator of in vivo
coagulation and it is not expressed in circulation under healthy
conditions. Nevertheless, under inflammatory conditions, TF
is expressed in endothelial and fibroblast cells and released to
the circulatory system due to the action of proinflammatory
cytokines, C reactive protein, and final products of advanced
glycation (55–57). GzmA and GzmK could contribute to
enhanced activation of the coagulation cascade in sepsis by
generating cytokines involved in endothelial cell activation and
coagulation like TNF-α or IL6 (58–60). GzmB is able to enhance
the proinflammatory activity of IL-1α by proteolytic cleavage
(61), although as indicated above, GzmB deficiency does not
protect from sepsis.
Gzms can alsomodulate the coagulation cascade irrespectively
of its ability to induce inflammatory cytokines. It has been
reported that GzmB and GzmM can degrade coagulation-
related substrates such as Von Willebrand factor (VWF) (30)
or fibrinogen (only GzmB) (62). VWF is a homeostatic plasma
protein that promotes platelet adhesion. Furthermore, VWF
stabilizes coagulation factor VIII (FVIII) in plasma protecting
it from proteolytic degradation and prolonging FVIII half-
life. In septic patients, increased levels of VWF have been
reported, so this protein could be a link between inflammation
and thrombosis (63). VWF is regulated by the metalloprotease
ADAMTS13, which specifically cleaves VWF in its A2 domain
(64). It has been reported that GzmB and GzmM could
mimic the action of ADAMTS13 by cleaving VWF regulating
its adhesive function and preventing its binding to FVIII
although did not affect platelet aggregation (30, 62). If these
processes are relevant in vivo during sepsis, GzmB and GzmM
would be expected to attenuate coagulation, preventing systemic
coagulation and organ failure. This would explain why GzmB
deficiency does not protect from sepsis, but would not explain
the increased resistance of GzmM deficient mice to endotoxicosis
and the reduced coagulation activity observed in these mice.
It should be expected that VWF lost procoagulatory activity
after cleavage and, thus, GzmM would protect from systemic
coagulation disorders. A similar paradox has been found for
GzmA. GzmA has been found to activate pro-urokinase, an
enzyme that presents anticoagulant activity (65). However, the
detrimental role of GzmA in sepsis has been confirmed by several
independent groups, suggesting that the in vitro function of
Gzms in regulating proteins involved in coagulationmight not be
relevant during sepsis in vivo. However, this hypothesis should be
clarified by analyzing specifically the role of Gzms in regulating
the coagulation system in vivo.
Regulation of Platelet Function
Platelets also play an important role in sepsis pathophysiology
since the presence of thrombocytopenia is frequent in these
patients. The role of platelets in sepsis is very complex as they can
contribute to sepsis pathophysiology at different levels beyond
regulation of haemostasis (66). Platelets can be directly activated
by endotoxins, proinflammatory cytokines, or proteases such
as thrombin (52, 67, 68). They contribute to the generation of
inflammatory responses and, among other mediators, it has been
shown that platelets can express GzmA and GzmB (18, 69, 70).
Platelets can form clots on the endothelial damaged surface which
produces elevated levels of VWF which is used as a marker for
endothelial damage. It has been reported that the presence of
proinflammatory cytokines such as IL-6, IL-8, and TNF-α (all
of them induced by GzmA) are capable of induce the liberation
of large VWF multimers that is a potent platelet aggregator.
In septic patients, it has been observed elevated levels of VWF
antigen which is related to a poor sickness prognosis (71). Here,
as indicated above, since GzmB and GzmM have been found
to cleave VWF and interfere with its procoagulant activity, it
is tempting to speculate that these Gzms might have regulatory
activities to prevent excessive VWF activity and clotting.
Curiously, GzmA was found to interact with the thrombin
receptor (PAR1) in platelets and block thrombin-mediated
responses (72). Although this interaction was not sufficient
to induce per se platelet activation and aggregation, it
might be possible that it can potentiate the effect of other
ligands like endotoxin, a suggestion that has not been
experimentally validated.
More recently it has been shown that during aging human
platelets acquire GzmA expression which contributes to the
generation of proinflammatory cytokines in monocytes (18). In
light of these recent findings it will be interesting to analyse
if Gzm expression is increased in older patients suffering from
sepsis and its correlation with disease severity. Finally, as it will
be discussed in the next section, it has been found that GzmB is
expressed in platelets during sepsis using a mouse polymicrobial
peritoneal sepsis model and might contribute to some of the
alterations in vascular biology observed during sepsis (70).
Endothelial Barrier Permeability: Any Role
for Protease Activating Receptors (PARs)?
The fluid redistribution to the extravascular space observed
during sepsis is a consequence of an increase in the endothelial
permeability or of the barrier function loss. Previous studies
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suggest that the change in the membrane permeability is a
consequence of the enzymatic cleavage of intercellular junction
proteins, which results in a structural damage of endothelial
cells. In vivo and in vitro studies have demonstrated that
TNF-α is one of the responsible cytokines of this disorder
and also that thrombin could potentiate them (73). Since
some Gzms like GzmA and GzmM seem to be inflammatory
mediators responsible of the detrimental effects of LPS in sepsis,
including TNF-α production, they also could contribute to
altered endothelial permeability.
The link between coagulation and inflammation has shown
that the family of PARs play an important role because
various proteases activated in the coagulation cascade will
induce inflammation through PAR receptors. Activation of
these receptors in endothelial cells critically contributes to
the regulation of endothelial permeability. This family consists
of four members, PAR-1,-2,-3,-4, that are expressed in cells
present in the vasculature such as endothelial cells, monocytes,
macrophages, platelets, fibroblasts and smoothmuscle cells. PAR-
1 is activated by thrombin, FXa (Activated factor X), trypsin
and APC (Activated Protein C). It has also been reported that
GzmA, B, and K are able to activate PAR1 in different cell types
(21, 23, 27, 28). In contrast, PAR-2,-3 or−4 have not been found
to be activated by any Gzm, albeit PAR2 participation in colitis
has been indirectly proposed (74). Here it should be noted that
neither activation of PAR2 by GzmA nor GzmA contribution to
colitis were analyzed in the later study. Thus, it is not clear yet
if PAR2 is activated by GzmA and the role of PAR2 in GzmA-
mediated cytokine induction. A recent study found that a PAR-
2 inhibitor (I-343) inhibited foot swelling induced by in vivo
administration of GzmA (48). This result suggests that PAR-2
could be directly or indirectly involved in some of the biological
functions of GzmA, but its specific role in the regulation of
GzmA-mediated inflammatory cytokine production will require
further experimental validation.
Despite the role of PAR-1 and 2 in the regulation of vascular
biology and endothelial cell activation, its contribution to the
pathophysiology of sepsis is complex and not completely clarified
(47). Some data suggest that multiple activation of PAR receptors
by coagulation proteases may contribute to inflammation in
endotoxemia and in sepsis (75). However, it was found that
PAR1 and/or PAR2 deficiency neither reduce the inflammatory
response nor increase survival in a mouse model of endotoxemia,
indicating that PAR1 and PAR2 are dispensable for LPS-induced
sepsis (76, 77). In a later study, using PAR antagonists in wild
type mice, it was shown that the role of PAR1 and PAR2 in
sepsis is reversal, being detrimental in the early phase of sepsis
and beneficial in later stages and thus, the net balance of PAR
deficiency during sepsis was indistinguishable between wild type
and PAR deficient mice (78). In contrast to PARs deficient mice,
GzmA deficient mice are protected from endotoxemia and sepsis
and, thus, PAR1 and 2 should not play an important role in
GzmA-induced inflammation during sepsis.
PARs are expressed by a variety of cells and the function in
each cell type might differ, which would explain the differences
between the in vitro and the in vivo observations regarding
PAR-1, GzmA, and sepsis. GzmA has been shown to activate
PAR1 in neurons (21), but not in platelets (72) or monocytes
(16). We have found that albeit a PAR-1 inhibitor, Vorapaxar,
reduced IL6 production in mouse macrophages stimulated
with GzmA, the protease was able to induce the same level
of IL6 in macrophages from wt or PAR1 deficient mice
(Santiago et al. Cell Reports, Accepted), indicating that PAR1 is
dispensable for GzmA-induced inflammation in macrophages.
This apparent contradictory result might be explained by the
potential unspecific effects of Vorapaxar including toxicity (79).
Whatever it is, it supports the previous findings suggesting that
PAR1 is not activated by GzmA in platelets or monocytes (16, 72).
In addition, it should be taken into account that even PAR1 could
be activated in some cell types, its relative contribution to GzmA-
mediated inflammation should be validated by using adequate
inhibitors or genetic deficient cell models (KO or siRNA).
Regarding PAR-3 and−4, although they can be activated by
thrombin and other proteases its role during sepsis has not been
confirmed yet (80) and in addition there is not any evidence
relating Gzms and them.
It seems that in light of the different results pointing to a
complex regulation of PARs during sepsis, the involvement of
PARs in the detrimental effects of GzmA on vascular permeability





In addition to inflammatory cytokines and direct endothelial cell
activation, other factors involved in the maintenance of vascular
permeability could contribute to the loss of endothelial barrier
function during sepsis. Some of these biological processes have
been shown to be activated by Gzms in vitro like extracellular
matrix (ECM) degradation, generation of products from ECM
degradation with biological activity (matrikines) or killing of
endothelial and smooth muscle cells (Table 1). Although the
involvement of these processes in the mechanisms activated by
Gzms during sepsis has not been directly analyzed, we would like
to speculate on the potential implications of some of them.
Although GzmB deficiency does not increase survival during
endotoxemia (40) or bacterial sepsis (41, 81), some of the
biological functions of this protease might contribute to some
of the vascular alterations observed in sepsis. For example, it
has been shown that extracellular GzmB is able to directly kill
cells involved in the maintenance of vascular architecture like
endothelial and smooth muscle cells (25).
Gzm B Induces Smooth Muscle Cell Apoptosis in the Absence
of Perforin. This process is based in its ability to induce ECM
degradation and cell detachment (82, 83), which might activate
cell death by anoikis (26, 82). Alternatively GzmB could disrupt
endothelial cell barrier integrity by degrading proteins involved
in tight junctions like Zonulin-1, PECAM, JAM, or Cadherins
as previously shown (26). Later on it was found a role for
GzmB in VE-cadherin cleavage and endothelial permeability in
vitro and in vivo (84). In addition, ECM degradation by GzmB
has been shown to release vascular endothelial growth factor
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which could affect vascular permeability (85). GzmB has also
been found to affect wound healing, which was related to the
ability of this protease to degrade fibronectin (86). Last but
not least, it has been reported that GzmB may act on some of
components of the EC involved in fibrillogenesis such as fibrillin-
1 or decorin, increasing vascular permeability (87, 88), one of the
most important pathological events that occur in sepsis.
Among other cell sources, platelets (70) and mast cells (26)
have been found to express GzmB, but not perforin or GzmA, and
thus, these cells could be the source of extracellular GzmB leading
to its detrimental functions related with ECM degradation. In
addition, it was found that GzmB of CD8+T and NK cells
could modulate endothelial cell permeability and immune cells
transmigration as a mechanism involved in host protection
against viral infections (89). NK cells have been involved in sepsis
(90, 91) and thus unregulated NK cells responses leading to a
high release of GzmB due to PAMP-induced activation of NK cell
receptors could transform a physiological protective mechanism
into a pathological insult affecting endothelial cell permeability.
We would like to reiterate that the roles of GzmB in
coagulation or in vascular permeability have not been studied yet
in the context of a septic response and thus, all these hypotheses
will require experimental validation.
Regarding GzmA, this protease can also degrade some
proteins of the ECM like fibronectin or collagen IV (92,
93) and also could be released by NK cells during sepsis




With the improvement of intensive care services, the majority of
patients with sepsis are able to survive the hyperinflammatory
phase but enter a prolonged immunosuppression stage that has
been called "immunoparalysis” in which they will be susceptible
to secondary infections (94).
In the late stages of sepsis, murine studies reveal a
relatively constant balance in proinflammatory and anti-
inflammatory cytokines, although with a smaller magnitude
when compared to the acute phase. One of the key features
of immunosuppression in sepsis is the state of cellular
anergy that can begin to occur even in the early stages
of the disease (3, 95, 96). This immunosuppression stage is
characterized by a decrease in antigen presentation, alteration
in the expression of costimulatory molecules, and changes in
lymphocytes populations. Here some experimental evidences
acquired in different disease models suggest that some Gzms
might also contribute to the different alterations leading
to immunosuppression.
One of the causes of anergy is the decrease in antigen
presentation and dendritic cell maturation leading to impaired
protective cellular responses (97, 98). The function (expression
for HLA-II and co-stimulatory molecules) and number of several
antigen presenting cells has been found to be compromised in
sepsis correlating with reduced survival like dendritic cells or
monocytes (99–103). These alterations contribute to changes in
the cytokine profiles and alterations in lymphocyte populations.
Although a direct impact of Gzms on antigen cell presentation
has not been reported, GzmB might contribute to T cell
immunosuppression by different means. All the hypotheses
proposed below will require experimental validation in order to
show if Gzms can contribute to the immunosuppressive stage
in sepsis.
GzmB has been found to be expressed by human and mouse
Treg cells (104, 105) and contribute to immunosuppression
and cancer immune-evasion by inhibiting Tc and NK cell
responses in tumor models (106) or to control viral-induced lung
inflammation (107). Thus, it could be speculated that GzmB of
Treg cell could contribute to the cellular immunosuppression
observed in sepsis patients. T regulatory cells are known to
contribute to immune homeostasis preventing reactions against
self-healthy tissue and commensal microbiota. They inhibit the
immune response at different levels like B, CD4 Th1, CD8T cell,
andNK cell activation or dendritic cell maturation and it has been
found that sepsis patients present reduced numbers of CD4 Th1,
CD8T cell, andNK cell (108) and increased Treg cell number and
activity (109–111), which contributes to secondary infection.
Alternatively, GzmB is able to cleave the zeta chain of the T
cell antigen receptor (TCR) which renders un-functional T cells
(112), being another potential mechanism by which GzmB could
contribute to immunosuppression in septic patients.
More direct evidence on the role of Gzms in
immunosuppression was recently provided by Freishtat
et al., who reported that acute sepsis-induced alterations in the
megakaryocyte-platelet transcriptional axis result in strongly
cytotoxic platelets expressing GzmB. These platelets used GzmB
to kill CD4+T cells contributing to lymphodepletion (69). Later
on the same group reported that the mechanism of platelet-
mediated GzmB-dependent lymphotoxicity required cell to cell
contact and was perforin-independent (70).
CONCLUSIONS AND FUTURE
PERSPECTIVES
Sepsis is a global serious health problem for which early specific
diagnosis and optimized treatment is crucial in order to reduce
organ damage and improve survival. It is well-known the
importance and influence of inflammation in the development
and pathogenesis of sepsis (3, 5). However, the molecular bases
to understand the dysregulated inflammatory response during
sepsis are complex and often not well-understood. Indeed,
most experimental trials to reduce inflammation during sepsis
have not been successful and a positive impact on patient
survival has not been reported. Among other reasons the impact
of anti-inflammatory therapy on pathogen control by host
immune response and the risk of secondary infections could
contribute to the low efficacy observed during the trials with
these therapies. During the last years, cumulative experimental
evidences indicate that some members of the Gzm family,
especially GzmA, have a key role in modulating inflammation
and contribute to sepsis. Indeed, elevated levels of Gzms have
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been found in patients suffering from sepsis albeit the clinical
significance remains unclear. In addition, in vivo mouse models
show that GzmA deficiency protects from bacterial sepsis and
endotoxemia indicating that GzmA have the potential to be used
as biomarker and/or therapeutic target in sepsis (17, 40, 41).
A current limitation of these studies is that the therapeutic
potential of GzmA should be validated using a GzmA inhibitor
in animal models expressing the protease. In addition, all in
vivo studies have been performed using purified endotoxin or a
single bacterial agent, and sepsis is often induced by more than
a single microbial agent like peritoneal sepsis, one of the most
common causes of sepsis. Moreover, the model of endotoxemia
induced by LPS, albeit useful to study septic shock, does not
provide information on the impact of regulation of inflammation
on microbial infection.
Most studies in this field has been focused on the ability
of some Gzms like GzmA, GzmK, and GzmM to induce the
production of inflammatory cytokines in different cell types in
vitro including monocytes, macrophages, endothelial cells, or
fibroblasts. However, the role of GzmK in vivo has not been
analyzed yet and GzmM has only been validated in the LPS-
induced endotoxemia in vivo model. Apart from the ability
to regulate the generation of the cytokine storm associated to
the septic process and the consequences of this response to
coagulation disorders and organ damage, in vitro evidences
suggest that Gzms might also directly regulate other alterations
found in sepsis like coagulation cascades, platelets function,
or vascular permeability. Further experimental studies will be
required to find out the relevance of these results in animal
models in vivo, although it can be anticipated that it will not be
easy to separate the effects due to Gzm-induced inflammatory
cytokines from those that could be directly regulated by
these proteases.
Apart from the disorders related with the inflammatory
response leading to disseminated coagulation and organ damage,
as discussed above, Gzms might also contribute to the
immunosuppressive stage commonly observed in septic patients,
responsible for a high morbidity/mortality due to secondary
infections. Indirect evidences from other experimental models
suggest that someGzmsmight contribute to immunosuppression
and, thus, it might be worth to dedicate some efforts to find
out the role of Gzms in promoting immunosuppression and/or
anergy during sepsis.
Despite the limitations mentioned above and all the
hypotheses and speculations pending of experimental validation,
some Gzms like GzmA or GzmK might present an important
advantage in comparison with other inflammatory molecules
that have been proposed and tested as therapeutic targets.
GzmA or GzmK deficiency does not predispose to infection
and these animals are able to efficiently clear most experimental
infections (6, 113). Thus, targeting Gzms might reduce sepsis
pathology without compromising the host immune response
against the offending pathogen/s and, thus, enhancing the
chances of efficient antimicrobial treatment to re-establish
immune homeostasis and reduce immune-associated damage.
Before these therapies can be developed and tested in potential
clinical trials, it will be required to better understand the biology
of granzymes during sepsis and the mechanisms involved.
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